A recent era in HIV prevention is underway in both Zimbabwe and Kenya, with the rollout of lenacapavir, a long-acting injectable medication. The move represents a significant step forward in the fight against HIV, offering a new option for individuals at high risk of contracting the virus and potentially reshaping prevention strategies across the African continent. This innovative approach to HIV prevention, known as long-acting injectable PrEP, aims to address challenges associated with daily oral medication adherence, a common barrier to effective prevention.
Zimbabwe began administering lenacapavir on Thursday, February 19, 2026, becoming one of the first countries globally to offer the drug as part of its national HIV response. The program, funded by the U.S. And the Global Fund, will initially target more than 46,000 individuals identified as being at high risk of HIV infection across 24 sites nationwide. Health Minister Douglas Mombeshora described the introduction of lenacapavir as a “milestone” in Zimbabwe’s efforts to curb new infections, according to New Zimbabwe.
Kenya’s Phased Rollout of Lenacapavir
Just days prior, on February 17, 2026, Kenya received its first shipment of 21,000 starter doses of lenacapavir. The Ministry of Health plans a phased, evidence-driven rollout, prioritizing areas with the highest HIV burden. Phase one, scheduled to begin in March 2026, will focus on 15 high-burden counties. Subsequent phases will progressively expand coverage across the country, ensuring adequate service preparedness and a reliable supply of the medication, as detailed by the Kenya Ministry of Health.
How Lenacapavir Works and Why It’s Significant
Lenacapavir is a first-in-class capsid inhibitor, meaning it works by disrupting the protein shell that surrounds the virus, preventing it from infecting cells. Unlike existing daily oral PrEP (pre-exposure prophylaxis) medications, lenacapavir is administered as an injection, significantly reducing the frequency of required dosing. Here’s particularly advantageous for individuals who may struggle with daily adherence, offering a more discreet and convenient prevention option. The drug has been shown to be highly effective in clinical trials, providing a robust level of protection against HIV acquisition.
The arrival of lenacapavir in Zimbabwe and Kenya is particularly impactful given the ongoing challenges in HIV prevention across sub-Saharan Africa. Despite significant progress in recent decades, the region remains disproportionately affected by the epidemic. Factors such as poverty, limited access to healthcare, and stigma continue to hinder prevention efforts. Long-acting injectable PrEP has the potential to overcome some of these barriers, reaching populations that may not consistently engage with traditional healthcare services.
Addressing Challenges and Ensuring Equitable Access
While the rollout of lenacapavir is a cause for optimism, challenges remain. Ensuring equitable access to the drug will be crucial, particularly for vulnerable populations. The phased rollout in Kenya, guided by epidemiological trends, is a step in this direction. Sustaining a reliable supply chain and maintaining adequate healthcare infrastructure will also be essential for the long-term success of the program. The Ministry of Health in Kenya emphasized the importance of service preparedness and commodity supply in its rollout plan.
The success of these programs will also depend on ongoing monitoring and evaluation. Data collection and analysis will be critical to assess the effectiveness of lenacapavir in real-world settings and to identify any potential challenges or areas for improvement. Continued investment in HIV prevention research and development will be vital to ensure that new and innovative tools are available to combat the epidemic.
Related
